To be attributed with pleiotropism, statins need to show effects that are unrelated to plasma lipid lowering. In the studies of Nakamura et al. using fluvastatin, it is not clear that this was unequivocally the case. Furthermore, the observed effects of fluvastatin treatment on plaque stability may have been distorted by a potential effect of the drug on fibrinolysis. We conclude that more studies are required before it will be possible to say that fluvastatin influences plaque stability in this mouse model through a non-lipid-lowering mechanism.
|Translated title of the contribution||Statin pleiotropism and atherosclerotic plaque rupture|
|Pages (from-to)||353 - 354|
|Number of pages||2|
|Publication status||Published - Oct 2009|